CD274 and hematologic disorder: We further demonstrated the value of combining a TCB antibody with PD-L1 blockade for hematological malignancies using CD20-TCB (glofitamab), another “2:1” format TCB targeting CD20 on B cells and CD3 on T-cells (9, 48).